SeaStar Medical Holding Corporation Price & Performance (ICUCW)

SeaStar Medical has secured six FDA Breakthrough Device Designations, including two recent approvals for its Selective Cytopheretic Device in cardiac surgery patients. Despite these advances, the company’s 2024 net loss reached $24.8 million, with R&D and G&A expenses rising, highlighting ongoing commercialization and financial challenges.12

SeaStar Medical has welcomed new directors and gained FDA approval for the final labeling of its QUELIMMUNE device for pediatric use. These developments come as the company prepares for the initial commercial launch of QUELIMMUNE Pediatric, aiming to address hyperinflammation in vital organs for critically ill children.32

SeaStar Medical’s stock has declined over 10% in the past 10 days, closing at $1.25 with high volatility and low liquidity. Technical analysis points to a continued weak trend, with oversold signals and no support below current levels, making the risk/reward profile unattractive in the near term.45